fda glp-1 warning 2025 november letters warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain Data Integrity : Key Lessons – FDA Issues Warning Letters to

These include effects such as headaches, higher heart rate, anxiety, increased gastrointestinal distress, dehydration, and slower weight loss rates

2021;10(1):e21453

The new oral formulation delivers weight loss results comparable to its injectable counterpart in clinical studies

Some doctors prescribed Ozempic or other GLP-1 drugs off-label for weight loss to non-diabetic patients or even pediatric patients, without FDA approval and without giving adequate warnings about the risks

Same-day appointments may be available depending on provider availability

These peptides cannot be legally sold as dietary supplements or for over-the-counter use